Key facts
- This page summarizes Reid M. Huber's Form 4 filing for Tango Therapeutics, Inc. (TNGX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 08 Jun 2023, 21:34.
Reid M. Huber - 06 Jun 2023 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)
- Reporting relationship
- Director
- Issuer ticker
- TNGX
- Reported as of
- 06 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Jun 2023, 21:34:20 UTC
- Prior SEC filing
- 20 Jan 2023
- Next SEC filing
- 09 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Douglas Barry, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Reid M. Huber filed Form 4 for Tango Therapeutics, Inc. (TNGX) on 08 Jun 2023.
Change
- Previous filing in this sequence was filed on 20 Jan 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TNGX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +5,000
- Change %
- Price
- $0.000000
- Shares after
- 5,000
- Date
- 06 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TNGX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +30,000
- Change %
- Price
- $0.000000
- Shares after
- 30,000
- Date
- 06 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $3.55
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 6, 2024 and (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Footnote F2
This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year beginning on July 6, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.